Posted 20th May 2020 by Joshua Sewell
This article is republished with kind permission from BioVox.
Recent activities in the cell therapy field have prompted many investment funds to pour fresh and increasing capital into this space. In this review, we would like to share some observations and highlight a few of the questions that arise when new modalities cross the bridge from bench to bed.
Posted 6th January 2020 by Joshua Sewell
Alongside the talks at our conferences, the poster presentations are a huge part of the knowledge sharing that takes place. We’re thrilled to be able to take a closer look at this poster from the Research & Technology Series, presented by Wim van Esch and the team at Sanquin.
Deep Learning based detection of tumor tissue compartments improves prognostic immunoprofiling in muscle-invasive bladder cancer
Posted 11th November 2019 by Liv Sewell
Worldwide, bladder cancer (BC) is the 11th most commonly diagnosed cancer. In men, BC is the 7thmost commonly diagnosed cancer worldwide.Although men are more likely to develop BC than women, women present with more advanced disease and have worse survival rates.
Muscle-invasive bladder cancers (MIBC) are cancers that have grown into or through the muscle layers of the bladder wall.
Dr. Katharina Nekolla and Ansh Kapil and their team applied Deep Learning enabled pathology to better understand prognostic factors in MIBC. Here we review the significance of the research and share their original poster.
Posted 19th June 2019 by Joshua Sewell
During my eight years at the Max Planck Institute for Molecular Genetics in Berlin, I led a protein technologies group. We developed a protein expression library, and then high-content protein arrays. In total, we made arrays with 10,000 different human proteins.
Posted 17th June 2019 by Joshua Sewell
Flow cytometry is a powerful tool in drug discovery because it provides a way to understand the drug’s mechanism of action. In order to stratify a better target for patients, you often need to know where the drug is working, and what kind of pathway it is operating along.
Posted 12th June 2019 by Joshua Sewell
When conducting an experiment to identify biomarkers, it is crucial to design the experiment properly. 80-90% of all biomarker populations for the last 20 years have not and cannot be reproduced, and the main reason that biomarkers fail is that these experiments are not designed properly. In this post, I will outline two ways in which experiments are poorly designed, and then outline the technological and methodological solution in a later blog.
Posted 7th June 2019 by Joshua Sewell
One of the frustrations I have with Flow Cytometry is when companies present their amazing new findings at conferences, and it’s quite often about TMB cells. In my case, I work on these cells perhaps 20% of the time. The rest of the time I work on cells from other parts of the human body – bone marrow, lung, bronchoalveolar lavage, spleen – and in diverse animals such as mice, rats, and even sparrow, chicken, and mosquito.
Posted 31st May 2019 by Joshua Sewell
The ability to measure multiple forms of cell death simultaneously represents a significant development for such techniques. I have been using antibodies and more specific forms of dyes to identify mitochondrial activity and reactive oxygen in roughly fifty populations, whereas normally it would only be able to measure one at a time. I will be discussing this work at the Flow Cytometry Congress, and it could prove enormously beneficial to drug and immunotherapy development.